Acorah Software Products - Accounts Production19.4.351truetruefalsetrueNo description of principal activity17 October 202431 October 202531 October 202516025405Amal LamlilassShabbir TejaniAjay Kumar Tripathiiso4217:GBPiso4217:EURiso4217:USDxbrli:sharesxbrli:purexbrli:pure160254052024-10-16160254052025-10-31160254052024-10-172025-10-3116025405frs-bus:PrivateLimitedCompanyLtd2024-10-172025-10-3116025405frs-bus:FilletedAccounts2024-10-172025-10-3116025405frs-bus:Micro-entities2024-10-172025-10-3116025405frs-bus:EntityHasNeverTraded2024-10-172025-10-3116025405frs-bus:AuditExempt-NoAccountantsReport2024-10-172025-10-3116025405frs-bus:Director12024-10-172025-10-3116025405frs-bus:Director22024-10-172025-10-3116025405frs-bus:Director32024-10-172025-10-31
Registered number: 16025405
Novix Health Ltd
Financial Statements
For the Period 17 October 2024 to 31 October 2025
Novix Health Ltd
Balance Sheet
As At 31 October 2025
Balance Sheet
Registered number: 16025405
31 October 2025
£
Current assets
66
NET CURRENT ASSETS
66
TOTAL ASSETS LESS CURRENT LIABILITIES
66
NET ASSETS
66
CAPITAL AND RESERVES
66
Notes
1.General Information
Novix Health Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 16025405. The registered office is 150 Hinckley Road, Earl Shilton, LE9 7LE.
2.Average Number of Employees
Average number of employees, including directors, during the period was: NIL
-
For the period ending 31 October 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The financial statements were approved by the board of directors on 6 October 2026 and were signed on its behalf by: